Investor Class Action Filed by Barrack, Rodos & Bacine

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Investor Class Action Filed by Barrack, Rodos & Bacine Against Orexigen Therapeutics, Inc. ("OREX")

SAN DIEGO, March 12, 2015 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine ("Barrack"), www.barrack.com , a nationally recognized law firm with a proven track record of success in securities class actions, announced today that it commenced a class action lawsuit in the United States District Court for the Southern District of California on behalf of purchasers of Orexigen Therapeutics, Inc. ("Orexigen") (Nasdaq: OREX ) common stock during the period between March 3, 2015 and March 5, 2015, inclusive (the "Class Period"). The Case is No. 15-cv-557-CAB-MDD. The complaint alleges that Orexigen and certain of its executives violated the Securities Exchange Act of 1934, and seeks to recover damages on behalf of all purchases of Orexigen common stock during the Class Period.

Orexigen is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity, including Contrave, which it claims "regulates appetite and energy expenditure through [central nervous system] activity." Orexigen is headquartered in La Jolla, California, just north of Barrack, Rodos & Bacine's office in San Diego, California.

The Barrack complaint alleges that as part of the FDA post-marketing approval process for Contrave, Orexigen was required to conduct a new, randomize-blind, placebo-controlled study to evaluate the effects of long-term treatment with Contrave on the incidents of major adverse cardiac events, or "MACE," in overweight and obese subjects with cardiovascular disease or multiple cardiovascular risk factors, referred to as a "LIGHT study."

On March 3, 2015, Orexigen disclosed detailed interim results of its LIGHT study. However, according to media reports, Orexigen had been warned by the U.S. Food & Drug Administration ("FDA") about inappropriately releasing interim study data in the past and, thus, knew that it would not be appropriate to release interim LIGHT study results on March 3, 2015. With the company's March 3, 2015 disclosures, the price of Orexigen common stock increased by more than 30%, from a closing price of $5.79 on March 2 to a closing price of $7.64 on March 3, 2015. The stock closed at even higher prices the next two days – closing at $8.49 per share on March 4 and at $8.01 per share on March 5, 2015. Over the three days, more than 150 million shares of stock were traded.

However, after the close of trading on March 5, 2015, Forbes published an article entitled " Top FDA official Says Orexigen Study Result 'Unreliable', "Misleading ." As alleged in the Barrack complaint, the Forbes report contained comments from an FDA official charged with overseeing the Contrave post-marketing clinical trial program, who reportedly stated, among other things, that the interim data from the study was probably "unreliable," "misleading," and "likely false." The Forbes article commented that "[i]f Orexigen cannot find a way to set things right, it could face fines, civil penalties, or even the withdrawal of Contrave from the market."

After issuance of the Forbes article, the price of Orexigen stock fell significantly as trading resumed on March 6, 2015, falling to a low of $6.76 per share and resting at $7.10 per share by the close of the day.

If you purchased Orexigen common stock during the period from March 3, 2015 through March 5, 2015, you may be eligible to serve as a lead plaintiff and thereby participate in the direction of this litigation on behalf of the class members. If you wish to serve as a lead plaintiff, you are required to file a motion with the court no later than 60 days from March 10, 2015. If you would like to discuss this case or have any questions or information concerning this notice or your rights and interests as a purchaser of Orexigen stock, we encourage you to contact Stephen R. Basser or Samuel M. Ward of Barrack at (619) 230-0800, (215) 963-0600, or (212) 688-0782, or via email at sbasser@barrack.com or sward@barrack.com . You may view a copy of the complaint as filed at www.barrack.com .       

Barrack, Rodos & Bacine has significant expertise and experience prosecuting investor class actions. The firm has been appointed by courts to lead positions in litigating such legal disputes for almost 40 years. It has secured many of the largest securities class action recoveries in history, including one of the largest securities class action trial verdicts since the passage of the Private Securities Litigation Reform Act of 1995.  The firm has also achieved significant recoveries in securities class actions in the District Courts of California, including a recovery in excess of $1 billion. Please visit www.barrack.com for more information about the firm.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Cloud Security’s $26.8 Billion Test Is All About Execution

Updated Category News Views 65

A cloud dashboard that spits out ten thousand alerts is not protection; it is an expensive way to make a security team miserable. That frustration sits right in the middle of Frost & Sullivan’s projection that global cloud security revenue will climb from $8.4 billion in 2025 to $26.8 billion by 2031, a 21.4% compound annual growth rate. The number is hefty, no...

Continue Reading
Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 86

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Label-Free Detection Has a Solid, Narrow Growth Lane

Updated Category News Views 133

Biologics labs are turning into a far better hunting ground for analytical equipment than the old, broad-brush research story suggests. Label-free detection is not a giant market, and nobody should dress it up as one. But the projected move from $0.58 billion in 2026 to $0.85 billion by 2031 points to a useful 8.1% annual growth lane, driven by work researchers genuinely...

Continue Reading
Travel Disruptions Reveal the Value of Human Support

Updated Category News Views 95

Air travel’s ugly little secret surfaced again during the recent ground stop: a reservation is easy, but rescuing a trip is labor-intensive, fast-moving work. Internova Travel Group says its people across Travel Leaders Network, Global Travel Collection and ALTOUR moved quickly as cancellations piled up and travelers were left staring at busted itineraries. That is not...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 121

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Alabama Power's 2027 Cut Puts Data Centers to Work

Updated Category News Views 87

Data centers rarely arrive bearing a gift for ordinary power customers. Yet Alabama Power says its coming load growth will help cut customer rates by $160 million in 2027, beginning with January bills. In a utility world stuffed with requests for more money, that is a sharp change of pace. The company filed the reduction with the Alabama Public Service Commission on Nov....

Continue Reading

Top 5 Most Recently Viewed Articles

American Teachers Alliance Initiates Empowering Programs for Students

Updated Category News Views 143

Empowering Future Educators with College Chapters In a progressive move to inspire and support the upcoming generation of teachers, the American Teachers Alliance (ATA) has launched a significant initiative aimed at engaging college students across universities. This initiative introduces college student chapters, fostering a community where aspiring educators can enhance...

Continue Reading
Enhancing Enterprise Collaboration: Progress ShareFile and Microsoft 365

Updated Category News Views 190

Introduction to Progress ShareFile's New Features Progress, a leading provider of AI-driven digital experience and infrastructure software, is excited to announce significant advancements to its ShareFile platform. The recent updates mark a transformative leap in how enterprises collaborate using Microsoft 365, empowering teams to work more securely and efficiently. Deep...

Continue Reading
Shareholder Alert: Investigations on Major Mergers for 2025

Updated Category News Views 314

Investigating Significant Mergers in 2025 In the financial landscape, the merging of companies can significantly impact shareholders. Recognizing the importance of every shareholder's voice, we delve into several notable mergers that are under scrutiny as we approach votes critical to shareholders. As many companies opt for merger routes, understanding the implications of...

Continue Reading
Explore the Vibrant Daylight Shows Series in NYC's Hotspots

Updated Category News Views 181

Unveiling the Daylight Shows at Daylight Studio Experience the vibrant world of creativity at Daylight Studio, a prominent event venue nestled in two of New York City's most dynamic areas, Hudson Yards and Flatiron. With years of experience in supporting film, fashion, and artistic endeavors, Daylight Studio has secured its place as a go-to location for creatives and...

Continue Reading
Ventyx Biosciences Begins Phase 2a Trial for Parkinson’s Treatment

Updated Category News Views 138

Ventyx Biosciences Begins Phase 2a Trial for VTX3232 Ventyx Biosciences, Inc. (Nasdaq: VTYX), a company focused on creating innovative oral treatments for various inflammatory diseases, has announced the start of dosing for its Phase 2a clinical trial of VTX3232. This important trial is centered on individuals who have been diagnosed with the early stages of Parkinson’s...

Continue Reading